Rx Minute: Cancer Drug Abandonment and Early HIV Treatment

This month's edition of Rx Minute focuses on two major new studies. First, we highlight a new study in the Journal of Oncology Practice and the American Journal of Managed Care which found a surprisingly high rate of abandonment of oral anti-cancer drugs, with high cost-sharing as a key driving factor. Second, we recap a new study sponsored by the National Institute of Allergy and Infectious Disease that produced strong evidence that antiretroviral treatments can prevent HIV/AIDS transmissions. 
Cancer Drug Abandonment Common

Rx Minute: Adherence to Medicines Reduces Overall Health Care Costs

A new study published in Health Affairs finds that for patients with congestive heart failure, hypertension, diabetes, or dyslipidemia (lipid disorders including high cholesterol), adherence to medicines leads to lower total health care cost. While many studies have shown an association between taking medicines as prescribed and lower costs, this study uses a more robust methodology to mathematically account for other variables at play.

Disruptive Innovation and the Future of the Drug Lifecycle

I’m at the PhRMA 2013 Annual Meeting in San Diego, where a panel is discussing disruptive innovation and the new challenges and opportunities it opens for the biopharmaceutical industry.

It’s a great topic. 

#PhRMA13 Morning Panelists Off To a Rollicking Start

04.11.13 | By

The morning panels of PhRMA's Annual Meeting provided a welcome blast of new thinking on how to create a positive geography for innovation, and further how that science gets done. As an added bonus, California Lieutenant Governor Gavin Newsom gave a super-charged address explaining how a state in grave economic flux plans to keep their leadership in bioscience.

Disruptive Innovation: Success Breeds Longevity

Disruptive innovations in health care are often the drivers of new technologies and new treatments that enhance and build upon old modalities. The birth of osteopathic medicine in the 1870s can be seen as a “disruptive innovation” in its revolutionary approach to medical treatment.

Castellani: A Long-term Vision for Innovative Biopharmaceutical Research Sector Needed

04.11.13 | By

John Castellani, PhRMA’s president & CEO, opened today’s afternoon session of PhRMA’s Annual Meeting in San Diego in a speech calling on policymakers, healthcare stakeholders, biopharmaceutical industry critics and sector allies alike to recognize and leverage the value of innovative medicines.

PhRMA’s Contributions to The Fight Against Chronic Diseases

04.11.13 | By

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980. 

The expectation this year: Americans will spend $2.9 trillion on health care.  And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.  

John Castellani 2013 Annual Meeting Remarks

 Good afternoon and welcome back. I hope you enjoyed lunch and Dan Pink’s thought-provoking talk.

 We at PhRMA are thrilled to be in San Diego for this year’s meeting.

 I want to thank John Lechleiter and the Eli Lilly team for their work and contributions to this meeting. I also want to thank all the PhRMA Board Members and especially our incoming chairman Bob Hugin of Celgene who inherits the challenge of overseeing next year’s meeting.

Rx Minute: Implementation of Medicare Part D Followed by Significant Reductions in Nondrug Medical Spending

new study published in the Journal of the American Medical Association (JAMA) finds that implementation of the Medicare prescription drug plan in 2006 was followed by significant decreases in spending on nondrug medical expenditures among beneficiaries who previously had limited drug coverage. After Medicare Part D started, nondrug medical spending in this group was about $1,200 per year less than expected.

Rx Minute: Insurance Coverage for Chronically Ill Less Generous

recent study found that insurance coverage for chronically ill patients is less generous than those without a chronic condition, primarily due to higher cost sharing for prescription drugs. 


Subscribe to RSS - Opinion